Telix Pharmaceuticals to acquire RLS

Written by Emily J. Thompson, Senior Investment Analyst

Updated: Sep 22 2024

0mins

Acquisition Announcement: Telix Pharmaceuticals has agreed to acquire RLS, a radiopharmacy network, from its parent company for $230 million upfront, with potential additional payments of up to $20 million based on performance milestones.
Strategic Expansion: This acquisition will enhance Telix's manufacturing capabilities in North America and establish a new radiometal production network to support its operations and strategic partners.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.